Venlafaxine for acute heroin detoxification: A double-blind, randomized, control trial

Journal of Clinical Psychopharmacology

Volumn 28, Issue 2, 2008, Pages 189-194

  Lin, Shih Ku ^a,b   Chen, Chia Hui ^c   Pan, Chun Hung ^a  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLONIDINE; DIAMORPHINE; FEXOFENADINE; FLURAZEPAM; IBUPROFEN; LOPERAMIDE; LORAZEPAM; METOCLOPRAMIDE; PLACEBO; TRAZODONE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DETOXIFICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HOSPITAL DISCHARGE; HUMAN; INSOMNIA; MALE; MORNING DOSAGE; MUSCLE SPASM; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SLEEP TIME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; VOMITING; WITHDRAWAL SYNDROME;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CAPSULES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 40949094926     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31816727e2     Document Type: Article

References (36)

1. Ministry of Justice, Ministry of Education, Department of Health. Anti-Drug Report on Taiwan 2006. Taipei, Taiwan: Department of Health; 2006.
2. Franken IH, Hendriks VM. Predicting outcome of inpatient detoxification of substance abusers. Psychiatr Serv. 1999;50:813-817.
3. Gold MS, Redmond DE Jr, Kleber HD. Clonidine in opioid withdrawal. Lancet. 1978;1:929-930.
4. Gold MS, Redmond DE Jr, Kleber HD. Clonidine blocks acute opioid-withdrawal symptoms. Lancet. 1978;2:599-602.
5. Gowing LR, Farrell M, Ali RL, et al. Alpha2-adrenergic agonists in opioid withdrawal. Addiction. 2002;97:49-58.
6. Jasinski DR, Johnson RE, Kocher TR. Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry. 1985;42:1063-1066.
7. Washton AM, Resnick RB. Clonidine in opioid withdrawal: review and appraisal of clinical findings. Pharmacotherapy. 1981;1:140-146.
8. Amato L, Davoli M, Minozzi S, et al. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2005;3:CD003409.
9. Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse. 1991;17:119-128.
10. Nigam AK, Ray R, Tripathi BM. Buprenorphine in opioid withdrawal: a comparison with clonidine. J Subst Abuse Treat. 1993;10:391-394.
11. Boothby LA, Doering PL. Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm. 2007;64:266-272.
12. Maldonado R. Participation of noradrenergic pathways in the expression of opioid withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev. 1997;21:91-104.
13. el-Kadi AO, Sharif SI. The role of 5-HT in the expression of morphine withdrawal in mice. Life Sci. 1995;57:511-516.
14. Ahtee L. Chronic morphine administration decreases 5-hydroxytryptamine and 2-hydroxyindoleacetic acid content in the brain of rats. Med Biol. 1980;58:38-44.
15. Akaoka H, Aston-Jones G. Indirect serotonergic agonists attenuate neuronal opioid withdrawal. Neuroscience. 1993;54:561-565.
16. Tao R, Ma Z, Auerbach SB. Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine. J Pharmacol Exp Ther. 1998;286:481-488.
17. Cervo L, Rochat C, Romandini S, et al. Evidence of a preferential role of brain serotonin in the mechanisms leading to naloxone-precipitated compulsive jumping in morphine-dependent rats. Psychopharmacology (Berl). 1981;74:271-274.
18. Buydens-Branchey L, Branchey M, Reel-Brander C. Efficacy of buspirone in the treatment of opioid withdrawal. J Clin Psychopharmacol. 2005;25:230-236.
19. Rose JS, Branchey M, Wallach L, et al. Effects of buspirone in withdrawal from opioids. Am J Addict. 2003;12:253-259.
20. Debonnel G, Saint-Andre E, Hebert C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007;10:51-61.
21. Gur E, Dremencov E, Lerer B, et al. Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur J Pharmacol. 1999;372:17-24.
22. Hatanaka K, Yatsugi S, Yamaguchi T. Effect of acute treatment with YM992 on extracellular serotonin levels in the rat frontal cortex. Eur J Pharmacol. 2000;395:23-29.
23. Schreiber S, Backer MM, Pick CG. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett. 1999;273:85-88.
24. Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects - a possible opioid involvement in severe depression? J Mol Neurosci. 2002;18:143-149.
25. Markowitz JS, Patrick KS. Venlafaxine-tramadol similarities. Med Hypotheses. 1998;51:167-168.
26. McDowell DM, Levin FR, Seracini AM, et al. Venlafaxine treatment of cocaine abusers with depressive disorders. Am J Drug Alcohol Abuse. 2000;26:25-31.
27. Lu L, Su WJ, Yue W, et al. Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor. Life Sci. 2001;69:37-46.
28. Magalas Z, De Vry J, Tzschentke TM. The serotonin/noradrenaline reuptake inhibitor venlafaxine attenuates acquisition, but not maintenance, of intravenous self-administration of heroin in rats. Eur J Pharmacol. 2005;528:103-109.
29. Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opioid withdrawal. Am J Drug Alcohol Abuse. 1987;13:293-308.
30. Guy W. Clinical Global Impression (CGI). In: Rush AJ, ed. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:100-102.
31. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
32. Office of Applied Studies, Substance Abuse and Mental Health Services Administration. Discharges from Substance Abuse Treatment Services: Treatment Episode Data Set (TEDS), 2004. Rockville, MD: US Department of Health and Human Services, Public Health Service, Substance Abuse and Mental Health Services Administration; 2006.
33. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503-509.
34. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16:54S-59S; discussion 59S-61S.
35. Garcia-Portilla MP, Bascaran MT, Saiz PA, et al. Effectiveness of venlafaxine in the treatment of alcohol dependence with comorbid depression. Actas Esp Psiquiatr. 2005;33:41-55.
36. Peles E, Schreiber S, Naumovsky Y, et al. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord. 2007;99:213-220.